BY Clayton R. Boldt, Ph.D.

Fewer than 30% of the women in the U.S. with abnormal, benign lesions known as atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) – a condition that significantly increases their risk of developing breast cancer – take advantage of available preventive therapies that can significantly reduce that risk.

In an effort to improve those rates, Abenaa Brewster, M.D., professor of Clinical Cancer Prevention, worked with colleagues...

tamoxifen structure preventive therapy for breast cancer

BY Ron Gilmore

Exosomes — tiny, virus-size particles released by cancer cells — can bioengineer micro-RNA (miRNA) molecules resulting in tumor growth. They...